article A single approach to creating effective cancer and autoimmune disease therapeutics 8 January 2021 | By Dr H Michael Shepard (Enosi Life Sciences) Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
article Human 3D cell-based systems to research gout: drug discovery for a neglected disease 18 December 2020 | By Hannah Balfour (Drug Target Review) In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
news Genes associated with heavy alcohol use may also impact compulsive behaviour and addiction 15 January 2020 | By Hannah Balfour (Drug Target Review) A study suggests there may be common genetic pathways between alcohol use disorder and other addictions, so GWAS identification of affected genes could provide the targets for new therapies.
news Potential new target identified for the treatment of gout 30 October 2019 | By Rachael Harper (Drug Target Review) A new therapeutic target for gout has been identified which could lead to new treatment strategies that could improve the quality of life for patients who suffer from the condition.
news Fruit fly model for studying uric acid diseases developed 16 August 2019 | By Victoria Rees (Drug Target Review) Researchers have created a fruit fly model to investigate uric acid-related diseases such as diabetes to aid in drug development.
news CMPK2 inhibitor could lesson symptoms of common illnesses 27 July 2018 | By Drug Target Review CMPK2 inhibitors may reduce inflammation, pain and tissue damage in arthritis and gout and in Alzheimer’s may slow loss of cognitive function...
news New study reveals new drug target for gout & inflammatory diseases 7 July 2017 | By Niamh Marriott (Drug Target Review) Research reveals cathepsins as potential therapeutic targets in particulate-mediated inflammatory disease…
news Selecta Biosciences initiates Phase 1 clinical study of SEL-212 in gout 10 June 2015 | By Victoria White Selecta Biosciences has initiated a Phase 1 study to assess the safety, pharmacodynamic profile, and immunogenicity of pegsiticase, a component of SEL-212...